上述减持主体无一致行动人。 重要内容提示： ● 股东持有的基本情况 截至本公告披露日，南京乾靖创业投资合伙企业（有限合伙）（以下简称"南京乾靖"）持有广州安必平 医药科技股份有限公司（以下简称"公司"）1,677,265股股份，占公司总股本的比例为1.79%，该等股份 为南京乾靖于公司首次公开发行并上市前取得的股份，且已于2021年8月20日解除限售后上市流通。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 ● 减持计划的主要内容 因股东资金需求，南京乾靖拟通过集中竞价方式及大宗交易方式减持所持有的公司股份不超过1,677,265 股(含本数)，不超过公司目前总股本的1.79%。其中，通过集中竞价方式减持股份不超过935,676股(含本 数)，不超过公司目前总股本的1.00%；通过大宗交易方式减持股份不超过741,589股(含本数)，不超过公 司目前总股本的0.79%，上述减持自本公告披露之日起15个交易日之后的3个月内进行。 一、减持主体的基本情况 ■ 股东及 ...

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., due to funding needs, which may impact the company's stock performance and investor sentiment [3][9]. Shareholder Holding Situation - As of the announcement date, Nanjing Qianjing Venture Capital Partnership holds 1,677,265 shares, representing 1.79% of the total share capital of the company [2]. Reduction Plan Details - Nanjing Qianjing plans to reduce its holdings by up to 1,677,265 shares, with a maximum of 935,676 shares through centralized bidding and 741,589 shares via block trading, within three months after the announcement [3][6]. - The reduction will commence 15 trading days after the announcement [3]. Shareholder's Past Reduction Activities - Nanjing Qianjing is required to disclose reduction plans only if its holdings fall below 5% [5]. Compliance and Commitments - The shareholder has made commitments regarding the holding period and reduction methods, including not selling shares during the lock-up period and ensuring that any reduction price does not fall below the adjusted issue price [7][8]. - The company will adhere to relevant regulations and timely disclose information regarding the reduction [9].

Summary of Key Points Core Viewpoint - Nanjing Qianjing plans to reduce its holdings in Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. due to funding needs, with a total reduction not exceeding 1,677,265 shares, representing 1.79% of the company's total share capital [2][5]. Shareholder Holding Situation - As of the announcement date, Nanjing Qianjing holds 1,677,265 shares, accounting for 1.79% of the total share capital, which were acquired before the company's IPO and became tradable after August 20, 2021 [2][3]. Reduction Plan Details - Nanjing Qianjing intends to reduce its holdings through two methods: - A maximum of 935,676 shares (1.00% of total share capital) via centralized bidding - A maximum of 741,589 shares (0.79% of total share capital) through block trading - The reduction will take place within three months starting 15 trading days after the announcement [2][4]. Compliance and Commitments - Nanjing Qianjing has made commitments regarding its shareholding, including: - Adhering to lock-up agreements for shares held before the IPO - Ensuring that any reduction in shares within two years post-lock-up will not be below the issue price, adjusted for any corporate actions [3][4]. - The company will comply with relevant laws and regulations regarding share reductions and will disclose plans in advance [5].

Group 1 - The core announcement states that Nanjing Qianjing Venture Capital Partnership holds approximately 1.68 million shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.79% of the company's total share capital [2] - Nanjing Qianjing plans to reduce its holdings through centralized bidding and block trading, with a maximum reduction of approximately 1.68 million shares, which is 1.79% of the total share capital [2] - The planned reduction includes up to approximately 940,000 shares through centralized bidding (1% of total share capital) and up to approximately 740,000 shares through block trading (0.79% of total share capital) [2]

证券代码：688393 证券简称：安必平 公告编号：2025-033 广州安必平医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，南京乾靖创业投资合伙企业（有限合伙）（以下简称"南 京乾靖"）持有广州安必平医药科技股份有限公司（以下简称"公司"）1,677,265 股股份，占公司总股本的比例为 1.79%，该等股份为南京乾靖于公司首次公开发 行并上市前取得的股份，且已于 2021 年 8 月 20 日解除限售后上市流通。 减持计划的主要内容 1 根据相关法律、法规的规定及股东承诺，南京乾靖持股低于 5%后，仅通过集中竞价方 式减持需要披露减持计划。 因股东资金需求，南京乾靖拟通过集中竞价方式及大宗交易方式减持所持有 的公司股份不超过 1,677,265 股(含本数)，不超过公司目前总股本的 1.79%。其 中，通过集中竞价方式减持股份不超过 935,676 股(含本数)，不超过公司目前总 股本的 1.00%；通过大宗 ...

人民财讯8月13日电，安必平(688393)8月13日晚间公告，公司持股1.79%的股东南京乾靖创业投资合伙 企业(有限合伙)(简称"南京乾靖")拟通过集中竞价及大宗交易方式，减持公司股份不超过167.73万股 (含)，即不超过公司目前总股本的1.79%。 ...

格隆汇8月13日丨安必平(688393.SH)公布，因股东资金需求，南京乾靖拟通过集中竞价方式及大宗交易 方式减持所持有的公司股份不超过167.73万股(含本数)，不超过公司目前总股本的1.79%。其中，通过集 中竞价方式减持股份不超过93.57万股(含本数)，不超过公司目前总股本的1.00%；通过大宗交易方式减 持股份不超过74.16万股(含本数)，不超过公司目前总股本的0.79%，上述减持自本公告披露之日起15个 交易日之后的3个月内进行。 ...

8月13日，医疗器械行业上涨0.09%，今日主力资金流出7.93亿元，成分股40只上涨，57只下跌。 主力资金净流出居前的分别为安必平（1959.61万元）、美好医疗（1874.35万元）、ST凯利（1873.81万 元）、超研股份（1867.59万元）、万孚生物（1671.12万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1688108赛诺医疗29.517.481.19亿元3.43%2300289利 德曼11.334.916644.74万元4.8%3870199倍益康47.346.533963.65万元10.19%4688068热景生物 232.611.413236.01万元5.98%5300238冠昊生物18.283.753164.59万元8.39%6688277天智航- U19.232.181872.46万元7.35%7002022科华生物7.742.111469.12万元6.4%8603987康德莱9.340.971360.65 万元4.53%9688271联影医疗131.04-0.11182.31万元2.08%10300653正海生物22.58-0.881148.09万元8.24% 来源：金 ...

从严监管为市场"定心提气" 不同于安必平股东高位违规套现，久量股份股东、前任董事郭子龙则是因违反"减持价格不低于发行 价"承诺，而构成违规减持。 据查询，5月9日，郭子龙通过集中竞价方式累计减持久量股份78.13万股，成交均价10.75元/股，成交金 额839.9万元。此次减持价格低于久量股份首次公开发行的发行价11.04元/股。郭子龙此前曾承诺："如 本人在承诺锁定期满后两年内减持所持有的公司股份的，减持价格不低于本次发行的发行价。" 减持行为发生在被立案调查期间或被行政处罚6个月内，也将构成违规减持。今年3月，汤姆猫持股5% 以上股东王健因质押股份融资违约，被相关债权人以集中竞价交易方式减持196万股，涉及金额1219万 元。而在减持前约1个月，王健刚因内幕交易被行政处罚300万元。深交所由此下发监管函，要求其充分 重视上述问题，吸取教训，及时整改，杜绝上述问题再次发生。 上海国家会计学院金融系主任叶小杰向记者表示，违规减持行为屡禁不止，可以从客观优势和主观动机 两个方面来看。一方面，大股东、董监高作为关键少数，通常掌握信息优势。例如，在定期报告或其他 重大事件披露之前，他们是最早接触到相关信息的，因此在 ...

Group 1 - The core viewpoint of the news is that Anbiping (688393) has experienced a decline in revenue and profit in its latest quarterly report, indicating potential challenges for the company [1][3] - As of August 11, 2025, Anbiping's stock closed at 31.62 yuan, with a 1.84% increase and a turnover rate of 3.41% [1] - The company's main funds saw a net outflow of 18.39% of the transaction amount, with significant outflows from large orders [1] Group 2 - Anbiping reported total operating revenue of 72.54 million yuan for the first quarter of 2025, a year-on-year decrease of 28.51% [1] - The net profit attributable to the parent company was 11.06 million yuan, down 238.49% year-on-year, while the non-recurring net profit decreased by 370.16% to 12.97 million yuan [1] - The company's liquidity ratios are strong, with a current ratio of 10.333 and a quick ratio of 8.947, while the debt-to-asset ratio stands at 8.25% [1] Group 3 - Anbiping has made investments in 16 companies and participated in 611 bidding projects, indicating active engagement in business development [2] - The company holds 29 trademark registrations and 91 patents, along with 92 administrative licenses, showcasing its focus on intellectual property [2]